0001193125-20-094871 S-8 4 20200402 20200401 20200402 Stealth BioTherapeutics Corp 0001696396 2834 000000000 E9 1231 S-8 33 333-237541 20766862 190 ELGIN AVENUE GEORGE TOWN GRAND CAYMAN E9 KY1-9005 617-600-6888 190 ELGIN AVENUE GEORGE TOWN GRAND CAYMAN E9 KY1-9005 S-8 1 d910576ds8.htm S-8 S-8

As filed with the Securities and Exchange Commission on April 1, 2020

Registration No. 333-                

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM S-8

REGISTRATION STATEMENT

UNDER

THE SECURITIES ACT OF 1933

 

 

Stealth BioTherapeutics Corp

(Exact Name of Registrant as Specified in Its Charter)

 

 

 

Cayman Islands   Not Applicable

(State or Other Jurisdiction of

Incorporation or Organization)

 

(I.R.S. Employer

Identification No.)

Stealth BioTherapeutics Corp

c/o Intertrust Corporate Services

(Cayman) Limited

190 Elgin Avenue, George Town

Grand Cayman

KY1-9005 Cayman Islands

  Not Applicable
(Address of Principal Executive Offices)   (Zip Code)

2020 ADS Incentive Plan

(Full Title of the Plan)

Stealth BioTherapeutics Inc.

275 Grove Street, Suite 3-107

Newton, MA 02466

(Name and Address of Agent For Service)

(617) 600-6888

(Telephone Number, Including Area Code, of Agent For Service)

 

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer

 

  

Accelerated filer

 

Non-accelerated filer

 

  

Smaller reporting company

 

    

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

 

 

CALCULATION OF REGISTRATION FEE

 

Title of Securities

to be Registered(1)

 

Amount

to be
Registered(2)

  Proposed
Maximum
Offering Price
Per Share
 

Proposed
Maximum
Aggregate

Offering Price

 

Amount of

Registration Fee

Ordinary Shares, $0.0003 par value per share

  24,999,996(3)   $1.32(4)   $32,999,995(4)   $4,283.40

 

(1)

American Depositary Shares (“ADSs”) issuable upon deposit of the ordinary shares registered hereby have been registered under a separate registration statement on Form F-6 (File No. 333-229509), as amended. Each ADS represents 12 ordinary shares.

(2)

In accordance with Rule 416 under the Securities Act of 1933, as amended, this registration statement shall be deemed to cover any additional securities that may from time to time be offered or issued to prevent dilution resulting from stock splits, stock dividends or similar transactions.

(3)

Consists of 2,083,333 ADSs, representing 24,999,996 ordinary shares, issuable under the 2020 ADS Incentive Plan.

(4)

Estimated solely for the purpose of calculating the registration fee in accordance with Rule 457(c) and Rule 457(h) of the Securities Act of 1933, as amended, and based on the average of the high and low sale prices of the registrant’s ADSs on the Nasdaq Global Market on March 25, 2020.

 

 


PART I

INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS

 

Item 1.

Plan Information.

The information required by Item 1 is included in documents sent or given to participants in the plans covered by this registration statement pursuant to Rule 428(b)(1) of the Securities Act of 1933, as amended (the “Securities Act”).

 

Item 2.

Registrant Information and Employee Plan Annual Information.

The written statement required by Item 2 is included in documents sent or given to participants in the plans covered by this registration statement pursuant to Rule 428(b)(1) of the Securities Act.

PART II

INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

 

Item 3.

Incorporation of Documents by Reference.

The registrant is subject to the informational and reporting requirements of Sections 13(a), 14, and 15(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), applicable to foreign private issuers, and in accordance therewith files reports and other information with the Securities and Exchange Commission (the “Commission”). The following documents, which are on file with the Commission, are incorporated in this registration statement by reference:

(a)     Annual Report on Form 20-F for the fiscal year ended December 31, 2019, filed with the SEC on April 1, 2020.

(b)    All other reports filed pursuant to Section 13(a) or 15(d) of the Exchange Act since the end of the fiscal year covered by the registrant document referred to in (a) above.

(c)     The description of the securities contained in the registrant’s registration statement on Form 8-A (Registration No. 001-38810) filed with the Commission on February 12, 2019, under the Exchange Act, including any amendment or report filed for the purpose of updating such description.

All documents subsequently filed by the registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act, prior to the filing of a post-effective amendment which indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference in this registration statement and to be part hereof from the date of the filing of such documents. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for the purposes of this registration statement to the extent that a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this registration statement.

 

Item 4.

Description of Securities.

Not applicable.

 

Item 5.

Interests of Named Experts and Counsel.

Not applicable.

 

Item 6.

Indemnification of Directors and Officers.

Every director and officer is indemnified and secured harmless out of the assets and funds of the Company against all actions, proceedings, costs, charges, expenses, losses, damages or liabilities incurred or sustained by such


director or officer in or about the conduct of the Company’s affairs or in the execution of such director or officer’s duties, powers, authorities or discretions, including any costs, expenses, losses or liabilities incurred by such director or officer in defending (whether successfully or otherwise) any civil proceedings concerning the Company or its affairs in any court whether Cayman Islands or elsewhere.

 

Item 7.

Exemption from Registration Claimed.

Not applicable.

Item 8. Exhibits.

 

Number   

Description

4.1    Amended and Restated Memorandum and Articles of Association of the Registrant (incorporated herein by reference to Exhibit 1.1 to the registrant’s Annual Report on Form 20-F, dated April 1, 2020)
4.2    Deposit Agreement among the Registrant, Citibank, N.A., as depositary, and all Owners and Holders of ADSs issued thereunder (incorporated herein by reference to Exhibit 99.3 to the registrant’s Report of Foreign Private Issuer on Form 6-K, dated as of March 4, 2019)
5.1    Opinion of Walkers
23.1    Consent of Walkers (included in Exhibit 5.1)
23.2    Consent of Deloitte & Touche LLP
24.1    Power of Attorney (included on the signature pages of this registration statement)
99.1    2020 ADS Incentive Plan (incorporated herein by reference to Exhibit 4.20 to the registrant’s Annual Report on Form 20-F, dated April 1, 2020)

 

Item 9.

Undertakings.

1.    Item 512(a) of Regulation S-K. The undersigned registrant hereby undertakes:

(1)    To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:

(i)    To include any prospectus required by Section 10(a)(3) of the Securities Act;

(ii)    To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement; and

(iii)    To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement;

provided, however, that paragraphs (i) and (ii) do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the registrant pursuant to Section 13 or Section 15(d) of the Exchange Act that are incorporated by reference in the registration statement.

(2)    That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.


(3)    To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

2.    Item 512(b) of Regulation S-K. The undersigned registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the registrant’s annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act that is incorporated by reference in the registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

3.    Item 512(h) of Regulation S-K. Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.


SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Newton, Massachusetts, on this 1st day of April, 2020.

 

Stealth BioTherapeutics Corp

 

By:  

/s/ Irene P. McCarthy

 

Irene P. McCarthy

Chief Executive Officer

POWER OF ATTORNEY AND SIGNATURES

We, the undersigned officers and directors of Stealth BioTherapeutics Corp, hereby severally constitute and appoint Irene P. McCarthy and Henry Hess, and each of them singly, our true and lawful attorneys with full power to them, and each of them singly, to sign for us and in our names in the capacities indicated below, the registration statement on Form S-8 filed herewith and any and all subsequent amendments to said registration statement, and generally to do all such things in our names and on our behalf in our capacities as officers and directors to enable Stealth BioTherapeutics Corp to comply with the provisions of the Securities Act of 1933, as amended, and all requirements of the Securities and Exchange Commission, hereby ratifying and confirming our signatures as they may be signed by our said attorneys, or any of them, to said registration statement and any and all amendments thereto.

Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated.

 

Signature

  

Title

 

Date

/s/ Irene P. McCarthy

Irene P. McCarthy

   Chief Executive Officer and Director (principal executive officer, principal financial officer and principal accounting officer)   April 1, 2020

/s/ Francis W. Chen

Francis W. Chen, Ph.D.

   Director   April 1, 2020

/s/ Gerald L. Chan

Gerald L. Chan, Sc.D.

   Director   April 1, 2020

/s/ Kevin F. McLaughlin

Kevin F. McLaughlin

   Director   April 1, 2020

/s/ Lu Huang

Lu Huang

   Director   April 1, 2020

/s/ Louis Lange

Louis Lange

   Director   April 1, 2020

/s/ Edward P. Owens

Edward P. Owens

   Director   April 1, 2020

 

STEALTH BIOTHERAPEUTICS INC.

Authorized Representative in the United States

 

By:  

/s/ Irene P. McCarthy

Name:   Irene P. McCarthy
Title:   Chief Executive Officer
EX-5.1 2 d910576dex51.htm EX-5.1 EX-5.1

Exhibit 5.1

 

1 April 2020    Our Ref: JSH/CB/S7050-154362

Stealth BioTherapeutics Corp

c/o Intertrust Corporate Services (Cayman) Limited,

190 Elgin Avenue,

Grand Cayman KY1-9005,

Cayman Islands

  

Dear Sirs

STEALTH BIOTHERAPEUTICS CORP

We have been asked to provide this legal opinion to you with regard to the laws of the Cayman Islands in connection with the registration by Stealth BioTherapeutics Corp (the “Company”), of 24,999,996 ordinary shares with a nominal or par value of $0.0003 per share in the capital of the Company (the “Shares”) for issuance under the Stealth BioTherapeutics Corp 2020 ADS Incentive Plan (the “Plan”), under the United States Securities Act of 1933, as amended (the “Securities Act”) and pursuant to the terms of the Registration Statement (as defined in Schedule 1).

For the purposes of giving this opinion, we have examined and relied upon the originals or copies of the documents listed in Schedule 1.

We are Cayman Islands Attorneys at Law and express no opinion as to any laws other than the laws of the Cayman Islands in force and as interpreted at the date of this opinion.

Based upon the foregoing examinations and the assumptions and qualifications set out below and having regard to legal considerations which we consider relevant, and under the laws of the Cayman Islands, we give the following opinion in relation to the matters set out below.

 

1.

The Company is an exempted company duly incorporated with limited liability, validly existing under the laws of the Cayman Islands and in good standing with the Registrar of Companies in the Cayman Islands (the “Registrar”).

 

2.

The Shares have been duly authorised by all necessary corporate action of the Company and upon the issue of the Shares (by the entry of the name of the registered owner thereof in the Register of Members of the Company confirming that such Shares have been issued credited as fully paid), and upon delivery and payment in accordance with the Memorandum and Articles of Association (as defined in Schedule 1) and the Plan and in the manner contemplated by the Registration Statement and the Prospectus (as each term is defined in Schedule 1), the Shares will be validly created, legally issued, fully paid and non-assessable (meaning that no additional sums may be levied on the holder thereof by the Company).

The foregoing opinion is given based on the following assumptions.

 

LOGO


1.

The originals of all documents examined in connection with this opinion are authentic. The signatures, initials and seals on the Documents are genuine and are those of a person or persons given power to execute the Documents under the Resolutions (as defined in Schedule 1). All documents purporting to be sealed have been so sealed. All copies are complete and conform to their originals. The Documents conform in every material respect to the latest drafts of the same produced to us and, where provided in successive drafts, have been marked up to indicate all changes to such Documents.

 

2.

We have relied upon the statements and representations of directors, officers and other representatives of the Company as to factual matters.

 

3.

The Company will receive consideration in money or money’s worth for each Share when issued, such price in any event not being less than the stated par or nominal value of each Share.

 

4.

The Resolutions have been duly executed by or on behalf of each Director and the signatures and initials thereon are those of a person or persons in whose name the Resolutions have been expressed to be signed.

 

5.

The Resolutions are and shall remain in full force and effect and have not been and will not be rescinded or amended.

 

6.

Each of the Registration Statement and the Plan (including each grant notice issued pursuant thereto) will be duly authorised, executed and delivered by or on behalf of all relevant parties prior to the issue of the Shares and will be legal, valid, binding and enforceable against all relevant parties in accordance with their terms under all relevant laws (other than the laws of the Cayman Islands).

 

7.

All preconditions to the issue of the Shares under the terms of the Plan will be satisfied or duly waived prior to the issue of the Shares and there will be no breach of the terms of the Plan.

 

8.

There are no records of the Company, agreements, documents or arrangements other than the documents and the company records expressly referred to herein as having been examined by us which materially affect, amend or vary the transactions envisaged in the Documents or restrict the powers and authority of the directors of the Company in any way or which would affect any opinion given herein.

 

9.

There is nothing under any law (other than the laws of the Cayman Islands) which would or might affect any of the opinions set forth above.

Our opinion as to good standing is based solely upon receipt of the Certificate of Good Standing issued by the Registrar. The Company shall be deemed to be in good standing under section 200A of the Companies Law on the date of issue of the certificate if all fees and penalties under the Companies Law have been paid and the Registrar has no knowledge that the Company is in default under the Companies Law.

This opinion is limited to the matters referred to herein and shall not be construed as extending to any other matter or document not referred to herein. This opinion is given solely for your benefit and the benefit of your legal advisers acting in that capacity in relation to this


transaction and may not be relied upon by any other person, other than persons entitled to rely upon it pursuant to the provisions of the Securities Act, without our prior written consent.

This opinion shall be construed in accordance with the laws of the Cayman Islands.

We hereby consent to the filing of this opinion as an exhibit to the Registration Statement. We also hereby consent to the reference to this firm in the Prospectus.

Yours faithfully

/s/ WALKERS

WALKERS


SCHEDULE 1

LIST OF DOCUMENTS EXAMINED

 

1.

The Certificate of Incorporation dated 3 April 2006 and the Fifth Amended and Restated Memorandum and Articles of Association of the Company adopted on 25 January 2019 (the “Memorandum and Articles of Association”).

 

2.

The Cayman Online Registry Information System (CORIS), the Cayman Islands’ General Registry’s online database, searched on 31 March 2020.

 

3.

A Certificate of Good Standing dated 18 March 2020 in respect of the Company issued by the Registrar (the “Certificate of Good Standing”).

 

4.

Copies of the executed written resolutions of the Directors of the Company dated 13 March 2020 and 31 March 2020 (the “Resolutions”) and the corporate records of the Company maintained at its registered office in the Cayman Islands.

 

5.

Copies of the following documents:

 

  (a)

the prospectus of the Company dated 6 February 2019 (the “Prospectus”), in connection with the registration statement on Form F-1, as amended (Registration No. 333-229097) filed by the Company with the United States Securities and Exchange Commission (“SEC”);

 

  (b)

the Registration Statement on Form S-8 filed on 1 April 2020 by the Company with the SEC registering the Shares under the Securities Act (as filed, the “Registration Statement”);

 

  (c)

2020 ADS Incentive Plan; and

 

  (d)

such other documents as we have deemed necessary to render the opinions set forth herein.

The documents listed in paragraphs (a) to (c) above inclusive are collectively referred to in this opinion as the “Documents”.

EX-23.2 3 d910576dex232.htm EX-23.2 EX-23.2

Exhibit 23.2

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We consent to the incorporation by reference in this Registration Statement on Form S-8 of our report dated April 1, 2020, relating to the consolidated financial statements of Stealth BioTherapeutics Corp appearing in the Annual Report on Form 20-F for the year ended December 31, 2019.

/s/ Deloitte & Touche LLP

Boston, Massachusetts

April 1, 2020

GRAPHIC 4 g910576g00i99.jpg GRAPHIC begin 644 g910576g00i99.jpg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end